P2.07-062 PIVOT-02: Phase 1/2 Study of NKTR-214 and Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumor Malignancies
Papadimitrakopoulou V, Tannir N, Bernatchez C, Haymaker C, Bentebibel S, Curti B, Wong M, Gergel I, Tagliaferri M, Zalevsky J, Hoch U, Aung S, Imperiale M, Cho D, Tykodi S, Puzanov I, Kluger H, Hurwitz M, Hwu P, Sznol M, Diab A. P2.07-062 PIVOT-02: Phase 1/2 Study of NKTR-214 and Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumor Malignancies. Journal Of Thoracic Oncology 2017, 12: s2153. DOI: 10.1016/j.jtho.2017.09.1318.Peer-Reviewed Original Research1212TiP PIVOT-02: A phase 1/2, open-label, multicenter, dose escalation and dose expansion study of NKTR-214 and nivolumab in patients with select, locally advanced or metastatic solid tumor malignancies
Diab A, Hurwitz M, Tannir N, Bernatchez C, Haymaker C, Bentebibel S, Curti B, Wong M, Gergel I, Tagliaferri M, Zalevsky J, Hoch U, Aung S, Imperiale M, Cho D, Tykodi S, Puzanov I, Kluger H, Hwu P, Sznol M. 1212TiP PIVOT-02: A phase 1/2, open-label, multicenter, dose escalation and dose expansion study of NKTR-214 and nivolumab in patients with select, locally advanced or metastatic solid tumor malignancies. Annals Of Oncology 2017, 28: v426-v427. DOI: 10.1093/annonc/mdx376.073.Peer-Reviewed Original ResearchMetastatic solid tumor malignanciesDose-expansion studySolid tumor malignanciesNKTR-214Phase 1/2Dose escalationTumor malignancyMulticenterNivolumabPatientsMalignancy